PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

Ngā tūemi rite

• PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
  mā: Kim Linton, me ētahi atu.
  I whakaputaina: (2023-08-01)
• P650: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES
  mā: K. Linton, me ētahi atu.
  I whakaputaina: (2022-06-01)
• C094 | BEXOBRUTIDEG (NX-5948), A NOVEL BRUTON’S TYROSINE KINASE DEGRADER, SHOWS HIGH CLINICAL ACTIVITY AND TOLERABLE SAFETY IN AN ONGOING PHASE 1A/B STUDY IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
  mā: P. Zinzani, me ētahi atu.
  I whakaputaina: (2025-09-01)
• P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
  mā: Xiaoyu Feng, me ētahi atu.
  I whakaputaina: (2023-08-01)
• C040 | BEXOBRUTIDEG (NX-5948), A NOVEL BRUTON’S TYROSINE KINASE DEGRADER, DEMONSTRATES RAPID AND DURABLE CLINICAL RESPONSES IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA UPDATED FINDINGS FROM AN ONGOING PHASE 1A STUDY
  mā: P. Zinzani, me ētahi atu.
  I whakaputaina: (2025-09-01)